Charles River Laboratories International (NYSE:CRL) Director James Foster Sells 33,561 Shares

Charles River Laboratories International, Inc. (NYSE:CRL) Director James Foster sold 33,561 shares of the stock in a transaction that occurred on Tuesday, August 25th. The stock was sold at an average price of $300.00, for a total transaction of $10,068,300.00. Following the transaction, the director directly owned 31,596 shares in the company, valued at approximately $9,478,800. This represents a 51.51% decrease in their position. The transaction was disclosed in a document filed with the Securities & Exchange Commission, which is available through this hyperlink. The transaction was executed under a pre-arranged Rule 10b5-1 trading plan.

Charles River Laboratories International Stock Up 0.6%

Shares of CRL opened at $296.94 on Friday. Charles River Laboratories International, Inc. has a fifty-two week low of $144.26 and a fifty-two week high of $303.31. The company’s fifty day moving average is $243.93 and its two-hundred day moving average is $196.64. The firm has a market cap of $14.18 billion, a PE ratio of -61.22, a price-to-earnings-growth ratio of 3.06 and a beta of 1.38. The company has a quick ratio of 1.04, a current ratio of 1.35 and a debt-to-equity ratio of 0.92.

Charles River Laboratories International (NYSE:CRL) last issued its earnings results on Wednesday, August 5th. The medical research company reported $3.02 earnings per share for the quarter, beating analysts’ consensus estimates of $2.77 by $0.25. Charles River Laboratories International had a positive return on equity of 15.75% and a negative net margin of 5.96%.The firm had revenue of $1 billion for the quarter, compared to analysts’ expectations of $980.53 million. During the same quarter last year, the firm earned $3.12 earnings per share. The firm’s revenue for the quarter was down 2.7% compared to the same quarter last year. Charles River Laboratories International has set its FY 2026 guidance at 11.150-11.450 EPS. Analysts forecast that Charles River Laboratories International, Inc. will post 11.33 earnings per share for the current year.

Institutional Inflows and Outflows

Institutional investors have recently made changes to their positions in the company. Continuum Advisory LLC acquired a new position in Charles River Laboratories International in the 2nd quarter worth $30,000. Los Angeles Capital Management LLC purchased a new stake in shares of Charles River Laboratories International during the fourth quarter worth about $42,000. Sfam LLC acquired a new position in shares of Charles River Laboratories International in the fourth quarter worth about $43,000. Activest Wealth Management lifted its stake in shares of Charles River Laboratories International by 10,900.0% in the fourth quarter. Activest Wealth Management now owns 220 shares of the medical research company’s stock worth $44,000 after acquiring an additional 218 shares in the last quarter. Finally, Geneos Wealth Management Inc. boosted its holdings in Charles River Laboratories International by 98.0% in the second quarter. Geneos Wealth Management Inc. now owns 293 shares of the medical research company’s stock valued at $44,000 after purchasing an additional 145 shares during the last quarter. 98.91% of the stock is owned by institutional investors and hedge funds.

Trending Headlines about Charles River Laboratories International

Here are the key news stories impacting Charles River Laboratories International this week:

• Positive Sentiment: Analysts raised longer-term earnings expectations. Zacks Research increased its FY2026 EPS estimate to $11.15 from $10.91, FY2027 to $12.49 from $12.11, and FY2028 to $13.82 from $13.01. Estimates were also raised for Q2 2027, Q3 2027, and Q1 2028, suggesting improving expectations for Charles River’s earnings outlook.
• Positive Sentiment: Global vaccine collaboration could support future demand. Medigen has partnered with Charles River in an effort to take an enterovirus vaccine global, potentially creating additional work for the company’s contract research and development services. Medigen links up with Charles River in push to take enterovirus vaccine global
• Neutral Sentiment: Wall Street sentiment remains a key focus. A recent report examines whether analysts are bullish or bearish on CRL, reflecting investor attention following the stock’s sharp advance and its elevated valuation. Is Wall Street bullish or bearish on Charles River Laboratories stock?
• Negative Sentiment: Director James C. Foster sold a substantial stake. Foster sold 33,561 shares for approximately $10.1 million at $300 per share, reducing his direct holdings by 51.5%. The transaction occurred under a pre-arranged Rule 10b5-1 plan, which lessens its significance as a discretionary bearish signal but may still weigh on sentiment. SEC insider transaction filing
• Negative Sentiment: Some near-term estimates were trimmed. Zacks lowered forecasts for Q3 and Q4 2026 EPS and Q1 2027 EPS slightly, while also reducing its Q4 2027 estimate. The revisions indicate modest near-term uncertainty despite the stronger full-year and longer-term outlook.

Analysts Set New Price Targets

CRL has been the subject of a number of research analyst reports. Sanford C. Bernstein set a $250.00 target price on shares of Charles River Laboratories International in a research report on Wednesday, July 1st. Evercore reaffirmed an “outperform” rating on shares of Charles River Laboratories International in a research report on Wednesday, August 5th. Weiss Ratings upgraded shares of Charles River Laboratories International from a “sell (e+)” rating to a “sell (d-)” rating in a research note on Wednesday, July 1st. Robert W. Baird set a $291.00 target price on shares of Charles River Laboratories International in a research note on Thursday, August 6th. Finally, Piper Sandler set a $300.00 target price on shares of Charles River Laboratories International in a report on Monday, August 10th. Twelve analysts have rated the stock with a Buy rating, three have assigned a Hold rating and one has given a Sell rating to the company’s stock. According to MarketBeat.com, the company presently has a consensus rating of “Moderate Buy” and an average price target of $255.65.

About Charles River Laboratories International

Charles River Laboratories International, Inc is a leading provider of research models and preclinical and clinical support services for the pharmaceutical, biotechnology and medical device industries. The company’s core offerings include discovery, safety assessment, toxicology, and pathology services, as well as supply of laboratory animals and related diagnostics. Services extend across in vivo and in vitro testing, biologics testing, and support for advanced therapies, helping clients accelerate drug development from early discovery through regulatory submission.

Founded in 1947 in Wilmington, Massachusetts, Charles River has grown through strategic investments and acquisitions to establish a broad portfolio of capabilities.